Skip to main content
TipRanks
Go Ultimate75% OFF
Trogenix logo

Trogenix: Valuation, Funding & Investors

Trogenix is a pioneering biotechnology company focused on developing innovative cancer therapies through its proprietary Odysseus® platform. The company specializes in creating precision genetic medicines that target aggressive, treatment-resistant cancers by delivering potent combination payloads that kill cancer cells and stimulate the immune system, while sparing healthy tissue. Trogenix's lead program targets glioblastoma, with additional efforts in colorectal cancer liver metastases and other solid tumors, aiming to transform cancer treatment paradigms with potentially curative "one-and-done" therapies.

Leadership & Board

Latest Estimated Valuation

Total Amount Raised
$70M
Total Funding Rounds
1
Latest Funding Amount
$70M
Latest Funding Round
Series A

Funding Round

Funding DateFunding RoundAmount RaisedPost-Money Valuation
Oct 08, 2025Series A$70.00M―

Similar Companies

A snapshot of private companies similar to Trogenix, helping you discover and navigate related company profiles.

Related News and Analysis